Key Highlights

  • 2.3% is the gap between Eli Lilly (NYSE:LLY) at USD 1,262.45 and its 52-week high of USD 1,292.65, per published market data on October 16, 2026 intraday. The 52-week low is USD 783.85, so shares sit 61.1% above it (own arithmetic).
  • USD 23.0 billion was second quarter revenue at Eli Lilly (NYSE:LLY), up 48%, as volume rose 60% and realized prices fell 13%, per the August 5, 2026 company release. Mounjaro sold USD 9.9 billion and Zepbound USD 4.9 billion.
  • USD 85.0 billion to USD 87.0 billion is raised 2026 revenue guidance, from USD 82 billion to USD 85 billion, with EPS guidance of USD 35.50 to USD 36.50. At the USD 36.00 midpoint, Eli Lilly (NYSE:LLY) trades at 35.1 times forward EPS (own arithmetic).
  • 3.55% was the October 15, 2026 gain to a USD 1,251.61 close for Eli Lilly (NYSE:LLY), with no company announcement identified. The stock is up 0.87% on October 16 with an RSI of 69.4, under the 70 overbought threshold.

Price Action and Valuation Context

Eli Lilly (NYSE:LLY) rose 0.87% to USD 1,262.45 on October 16, 2026 on relative volume of 0.2x early in the session, per published market data. The October 15 close of USD 1,251.61 gave a USD 1.12 trillion market value. No Lilly filing or release explains the 3.55% rise on October 15, and the move coincided with a 1.86% gain in the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), where Lilly is the largest holding at 15.33%. That points to sector rotation toward defensive names.

Volume, Price Erosion and Earnings Quality

Second quarter revenue grew 48% because volume rose 60% while realized prices fell 13%. Outside the United States, prices fell 36% mainly because Mounjaro joined China's national reimbursement list, which trades a lower price for wider access, and volume there rose 113%. Non-GAAP EPS of USD 8.38 included USD 3.03 of acquired development charges, so EPS excluding them was USD 11.41 (own arithmetic). The EPS range of USD 35.50 to USD 36.50 absorbs such charges, so revenue is the cleaner read on demand.

Pipeline, Analyst Views and Risks

Lilly submitted orforglipron, its oral GLP-1, for type 2 diabetes in the United States and plans a retatrutide filing in the first quarter of 2027. Morgan Stanley set a USD 1,430 target and Cantor Fitzgerald USD 1,440 earlier in October, both above the USD 1,262.45 quote. Risks are specific: falling price per unit, repeated acquired development charges, a 35.1 times forward multiple that leaves little room for a soft quarter, and a stock that has risen 61.1% from its low.

Where Things Stand

It depends. Eli Lilly (NYSE:LLY) can break USD 1,292.65, a level 2.3% above the quote, only if third quarter results on October 29, 2026 show volume still outweighing price erosion, because the October 15 rise had no company-specific trigger. Revenue up 48% and guidance raised to USD 85.0 billion to USD 87.0 billion support demand, and both analyst targets sit above the price. Against that, an RSI of 69.4 and a 35.1 times multiple leave less room for error, and rotation-driven rallies can reverse as quickly as they form.